What is Claimed is:

1. A crystalline compound or cocrystal comprising fasoracetam and a conformer, wherein the coformer is a non-aromatic organic compound and contains at least one moiety selected from $-NH_2$, $-NO_2$, and -C(=O)-X, C(=O)-OR_1, wherein R_1 is alkyl and X is a nitrogen containing moiety.

2. A crystalline compound or a cocrystal comprising fasoracetam, and a coformer wherein the coformer is an aromatic compound,

wherein the aromatic compound has at least one substituent chosen from -OH,$-NH_2$, alkyl, $-NO_2$, C_1-C_5 esters, and –COOH.

3. A crystalline compound or cocrystal comprising fasoracetam ((R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one) or (S)-5-(piperidine-1-carbonyl)pyrrolidin-2-one and 4-aminobenzoic acid.

4. A crystalline compound or cocrystal comprising fasoracetam and trimesic acid.

5. A crystalline compound or cocrystal comprising fasoracetam and R-ibuprofen.

6. A crystalline compound or cocrystal comprising fasoracetam and phloroglucinol.

7. A crystalline compound or cocrystal comprising fasoracetam and methyl-3,4,5-trihydroxybenzoate.

8. A crystalline compound or cocrystal comprising fasoracetam and ethyl gallate.

9. A crystalline compound or cocrystal comprising fasoracetam and phthalic acid.

10. A crystalline compound or cocrystal comprising fasoracetam and 6-hydroxy-2-napthoic acid.

11. A crystalline compound or cocrystal comprising fasoracetam and 4-nitrobenzoic acid.

12. A crystalline compound or cocrystal comprising fasoracetam and 2-indole-3-acetic aci.

13. A crystalline compound or cocrystal comprising fasoracetam and urea.

14. A pharmaceutical composition comprising a crystalline compound of any one of claims 1-13, or a cocrystal of any one of claims 1-13, and one or more pharmaceutically acceptable excipients.

15. Use of a crystalline compound of any of claims 1-13, a cocrystal of any of claims 1-13, or the pharmaceutical composition of claim 14, in the manufacture of a medicament for the treatment of attention-deficit hyperactive disorder in a human subject in need thereof.

16. A process for preparing a fasoracetam:urea cocrystal Form B comprising:

combining fasoracetam in a suitable solvent with urea to form a solution wherein the molar amount of urea to fasoracetam ranges from 0.7 to 1.2;

cooling the solution to form cocrystals of fasoracetam:urea cocrystal Form B,

wherein the fasoracetam is selected from the group consisting of fasoracetam Form I, fasoracetam Form II, the amorphous form of fasoracetam, anhydrate fasoracetam, and the Forms Mixture of fasoracetam.